Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324336 · ClinicalTrials.gov registry record
Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets
A clinical trial, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- 40
- Enrollment target
NCT01324336 is a clinical trial that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 40 participants.
The verdict
NCT01324336 has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).
Interventions
- DRUG 6-Mercaptopurine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324336
The ClinicalTrials.gov registry entry for NCT01324336 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 6-Mercaptopurine is the first listed.
NCT01324336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324336 about?
NCT01324336 is a clinical study titled "Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets". The purpose of this study is to compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT01324336?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2011-07. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01324336?
The interventions under investigation include: 6-Mercaptopurine (DRUG).
Who is sponsoring clinical trial NCT01324336?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.